In this investigation, skip cN2 metastases were documented in 60 (18.5%, 60/325) patients with cN2 stage NSCLC, and 54 (16.6%, 54/325) patients with cN2 stage NSCLC had non-skip cN2 metastases. This evidence concerns the gene CNDP2 and non-small cell lung carcinoma.